NO20050526L - Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling - Google Patents
Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandlingInfo
- Publication number
- NO20050526L NO20050526L NO20050526A NO20050526A NO20050526L NO 20050526 L NO20050526 L NO 20050526L NO 20050526 A NO20050526 A NO 20050526A NO 20050526 A NO20050526 A NO 20050526A NO 20050526 L NO20050526 L NO 20050526L
- Authority
- NO
- Norway
- Prior art keywords
- ppar
- agonist
- treatment
- weight gain
- alfa
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02291994A EP1388351A1 (fr) | 2002-08-08 | 2002-08-08 | Utilisation d'un fibrate pour le traitement d'obesité associée au traitement par le rosiglitazone |
EP02292830A EP1388352A1 (fr) | 2002-08-08 | 2002-11-14 | Utilisation d'un agoniste de PPAR-alpha pour traiter l'obesité associée au traitement avec un agonist de PPAR-gamma dans des patients |
PCT/EP2003/008756 WO2004018041A1 (fr) | 2002-08-08 | 2003-08-06 | Utilisation d'un agoniste de ppar alpha pour traiter une prise de poids liee a un traitement par les agonistes de ppar gamma |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20050526L true NO20050526L (no) | 2005-03-02 |
Family
ID=30445152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20050526A NO20050526L (no) | 2002-08-08 | 2005-01-31 | Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling |
Country Status (10)
Country | Link |
---|---|
US (2) | US20040110799A1 (fr) |
EP (2) | EP1388352A1 (fr) |
JP (1) | JP4588448B2 (fr) |
CN (1) | CN1674959A (fr) |
AT (1) | ATE536913T1 (fr) |
AU (1) | AU2003260380B2 (fr) |
CA (1) | CA2493747A1 (fr) |
ES (1) | ES2379165T3 (fr) |
NO (1) | NO20050526L (fr) |
WO (1) | WO2004018041A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT200600046A (es) | 2005-02-09 | 2006-09-25 | Terapia de combinacion |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5071773A (en) | 1986-10-24 | 1991-12-10 | The Salk Institute For Biological Studies | Hormone receptor-related bioassays |
ES2137915T3 (es) | 1987-09-04 | 2000-01-01 | Beecham Group Plc | Derivados de tiazolidindiona sustituida. |
US4981784A (en) | 1987-12-02 | 1991-01-01 | The Salk Institute For Biological Studies | Retinoic acid receptor method |
EP0497894A4 (en) | 1989-10-25 | 1993-03-31 | The Salk Institute For Biological Studies | Receptor infection assay |
EP0441483A3 (en) | 1990-01-16 | 1992-11-19 | Baylor College Of Medicine | Expression vectors that produce steroid receptors, steroid receptor chimera, screening assays for steroid receptors and clinical assays using synthesized receptors and receptor vectors |
AU655943B2 (en) | 1990-09-21 | 1995-01-19 | Salk Institute For Biological Studies, The | Functional antagonism between proto-oncoprotein c-jun and hormone receptors |
GB9027023D0 (en) | 1990-12-12 | 1991-01-30 | Wellcome Found | Anti-atherosclerotic aryl compounds |
AU666348B2 (en) | 1991-12-06 | 1996-02-08 | Salk Institute For Biological Studies, The | Multimeric forms of members of the steroid/thyroid superfamily of receptors |
CA2135644C (fr) | 1992-05-14 | 2009-01-27 | Elisabetta Vegeto | Recepteurs steroidiens mutants, modes d'utilisation et declencheur moleculaire servant a la therapie genique |
CA2160135A1 (fr) | 1993-04-07 | 1994-10-13 | Donald P. Mcdonnell | Methode pour depister les agonistes de recepteurs |
US5506102A (en) | 1993-10-28 | 1996-04-09 | Ligand Pharmaceuticals Incorporated | Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription |
CA2180271A1 (fr) | 1993-12-30 | 1995-07-06 | Ronald M. Evans | Nouvelles utilisations de produits de recombinaison de recepteurs de gal4 |
EP0888278B1 (fr) | 1996-02-02 | 2003-07-23 | Merck & Co., Inc. | Agents anti-diabete |
AU1856997A (en) | 1996-02-02 | 1997-08-22 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
JP2002515865A (ja) | 1996-02-02 | 2002-05-28 | メルク エンド カンパニー インコーポレーテッド | 抗糖尿病薬 |
ES2194179T3 (es) | 1996-02-02 | 2003-11-16 | Merck & Co Inc | Derivados heterociclicos como agentes antidiabeticos y antiobesidad. |
ES2241036T3 (es) | 1996-02-02 | 2005-10-16 | MERCK & CO., INC. | Procedimiento de tratamiento de diabetes y estados patologicos asociados. |
AU4050797A (en) * | 1996-08-02 | 1998-02-25 | Ligand Pharmaceuticals Incorporated | Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators |
TW438784B (en) | 1997-08-29 | 2001-06-07 | Ssp Co Ltd | Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same |
AU4713499A (en) * | 1998-06-27 | 2000-01-17 | Photogenesis, Inc. | Ophthalmic uses of ppargamma agonists and ppargamma antagonists |
US6329403B1 (en) * | 1998-06-30 | 2001-12-11 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for the treatment of diabetes |
MXPA02010316A (es) | 2000-04-19 | 2005-04-19 | Borody Thomas J | Terapia novedosa para los trastornos asociados con la hiperlipidemia. |
CA2415742A1 (fr) * | 2000-07-25 | 2002-01-31 | Merck & Co., Inc. | Indoles n-substitues utiles pour le traitement du diabete |
EP1320362B1 (fr) * | 2000-09-20 | 2011-08-31 | Jagotec AG | Microparticules de fibrate stabilisees |
WO2002028857A1 (fr) * | 2000-10-05 | 2002-04-11 | Dr. Reddy's Research Foundation | Polymorphes de chlorhydrates de pioglitazone et leur utilisation en tant qu'antidiabetiques |
CN100577175C (zh) * | 2001-04-04 | 2010-01-06 | 奥索-麦克尼尔药品公司 | 包括葡萄糖重吸收抑制剂和ppar调节剂的联合疗法 |
-
2002
- 2002-11-14 EP EP02292830A patent/EP1388352A1/fr not_active Withdrawn
-
2003
- 2003-08-06 ES ES03792272T patent/ES2379165T3/es not_active Expired - Lifetime
- 2003-08-06 WO PCT/EP2003/008756 patent/WO2004018041A1/fr active Application Filing
- 2003-08-06 AT AT03792272T patent/ATE536913T1/de active
- 2003-08-06 CN CNA038191350A patent/CN1674959A/zh active Pending
- 2003-08-06 AU AU2003260380A patent/AU2003260380B2/en not_active Ceased
- 2003-08-06 JP JP2004530101A patent/JP4588448B2/ja not_active Expired - Fee Related
- 2003-08-06 EP EP03792272A patent/EP1526894B1/fr not_active Expired - Lifetime
- 2003-08-06 CA CA002493747A patent/CA2493747A1/fr not_active Abandoned
- 2003-08-08 US US10/636,670 patent/US20040110799A1/en not_active Abandoned
-
2005
- 2005-01-31 NO NO20050526A patent/NO20050526L/no not_active Application Discontinuation
-
2008
- 2008-10-10 US US12/249,027 patent/US20090099238A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1388352A1 (fr) | 2004-02-11 |
WO2004018041A1 (fr) | 2004-03-04 |
US20090099238A1 (en) | 2009-04-16 |
CN1674959A (zh) | 2005-09-28 |
EP1526894B1 (fr) | 2011-12-14 |
ATE536913T1 (de) | 2011-12-15 |
AU2003260380A1 (en) | 2004-03-11 |
JP4588448B2 (ja) | 2010-12-01 |
EP1526894A1 (fr) | 2005-05-04 |
CA2493747A1 (fr) | 2004-03-04 |
US20040110799A1 (en) | 2004-06-10 |
JP2005539033A (ja) | 2005-12-22 |
AU2003260380B2 (en) | 2008-11-06 |
ES2379165T3 (es) | 2012-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20051521D0 (no) | Anvendelse av kombinasjonen av ciclesonid og antihistaminer for behandlingen av allergisk rhinitt | |
NO20051692L (no) | Anvendelse av indolylderivater for fremstilling av et medikament for behandling av allergisk rhinitt | |
DE50310516D1 (de) | Fredericamycin-derivate | |
PL374865A1 (en) | Treatment of tnf alpha related disorders | |
GB0318447D0 (en) | Therapeutic agents | |
GB0223038D0 (en) | Therapeutic compounds | |
EP1490044A4 (fr) | Therapie combinatoire pour le traitement de maladies faisant intervenir des composants inflammatoires | |
ATE356621T1 (de) | (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum | |
HK1080467A1 (en) | Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders | |
NO20055098D0 (no) | Anvendelse av 10-hydroksy-10,11-dihydrokarbamazepinderivater for behandling av affektive forstyrrelser | |
DE60312736D1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
HRP20050579B1 (hr) | Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol | |
DK1610864T3 (da) | Elektromagnetisk stimulering af patienter med osteoporose | |
NO20054700L (no) | Anvendelse av et fibrat og orlistat for behandling av fedme | |
ATE289196T1 (de) | Verwendung von pleuromutilinderivaten zur transdermalen behandlung bakterieller erkrankungen | |
NO20050526L (no) | Bruk av PPAR-ALFA agonist for behandling av vektokning forbundet med PPAR-GAMMA-agonistbehandling | |
IL162818A0 (en) | Combination therapy for the treatment of bacterialinfections | |
NO20045343L (no) | Ny kombinasjon for behandling av luftveisforstyrrelser | |
EA200600989A1 (ru) | Применение габоксадола для лечения бессонницы | |
TW200512183A (en) | 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia | |
NO20045344L (no) | Kombinasjon for behandling av luftveisforstyrrelser | |
NO20051468L (no) | Behandling av ikke-allergisk rhinitt med selektive fosfodiesterase-4-inhibitorer | |
ATE350034T1 (de) | Verwendung von epothilone zur behandlung hyperparathyreoidismus | |
NO20053612L (no) | 1,2,4-triaminobenzenderivater nyttige for behandling av forstyrrelser i sentralnervesystemet | |
HUP0101350A2 (hu) | Generalizált szorongásos rendellenesség kezelése paroxetinnel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |